Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Charles Swanton
Francis Crick Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
115 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Buenos Aires, Argentina
- Research Site
Camperdown, Australia
- Research Site
Melbourne, Australia
- Research Site
St Leonards, Australia
- Research Site
Hasselt, Belgium
- Research Site
Roeselare, Belgium
- Research Site
Barretos, Brazil
- Research Site
Florianópolis, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
São José do Rio Preto, Brazil
- Research Site
Vitória, Brazil
- Research Site
Victoria, British Columbia, Canada
- Research Site
Saint John, New Brunswick, Canada
- Research Site
Kingston, Ontario, Canada
- Research Site
Ottawa, Ontario, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Olomouc, Czechia
- Research Site
Ostrava, Czechia
- Research Site
Prague, Czechia
- Research Site
Marseille, France
- Research Site
Pessac, France
- Research Site
Saint-Herblain, France
- Research Site
Strasbourg, France
- Research Site
Athens, Greece
- Research Site
Athens, Greece
- Research Site
Heraklion, Greece
- Research Site
Holargos, Athens, Greece
- Research Site
Larissa, Greece
- Research Site
Thessaloniki, Greece
- Research Site
Hong Kong, Hong Kong
- Research Site
Jordan, Hong Kong
- Research Site
Budapest, Hungary
- Research Site
Budapest, Hungary
- Research Site
Gyöngyös - Mátraháza, Hungary
- Research Site
Győr, Hungary
- Research Site
Szolnok, Hungary
- Research Site
Székesfehérvár, Hungary
- Research Site
Törökbálint, Hungary
- Research Site
Bengaluru, India
- Research Site
New Delhi, India
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2020
- Primary completion
- 31 May 2023
- Completion
- 15 Jan 2024
- Last update posted
- 25 Jun 2024
- Registered enrollment
- 30
- Registry id
- NCT04642469
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.